TY  - JOUR
PY  - 2022//
TI  - The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis
JO  - Expert opinion on drug safety
A1  - Jawad, Muhammad Youshay
A1  - Di Vincenzo, Joshua D.
A1  - Ceban, Felicia
A1  - Jaberi, Saja
A1  - Lui, Leanna M. W.
A1  - Gillissie, Emily S.
A1  - Alnafeesi, Yazen
A1  - Rosenblat, Joshua D.
A1  - McIntyre, Roger S.
SP  - 841
EP  - 852
VL  - 21
IS  - 6
N2  - INTRODUCTION: Intranasal (IN) esketamine represents an innovative treatment for individuals with treatment resistant depression and depression with suicidal ideation and behavior. Herein, we synthesize extant long-term studies (≥ 4 weeks) regarding this treatment.  RESEARCH DESIGN AND METHODS: The interventional studies of IN esketamine in patients with depression having a study period of at least four weeks were included for our synthesis. A meta-analysis was undertaken for the efficacy and safety parameters of adjunctive IN esketamine vs IN placebo with an oral antidepressant. The data excluded from meta-analysis were synthesized narratively.  RESULTS: After pooling data from seven randomized controlled trials, treatment with adjunctive IN esketamine vs IN placebo was safe overall, and more effective at decreasing depressive symptoms (d = -0.239; 95%CI = -0.335,-0.142;p < 0.0001), with higher response (RR = 1.221; 95% CI = 1.055,1.428; p = 0.017) and remission (RR = 1.366; 95% CI = 1.182,1.578; p < 0.0001) rates. The year-long trials showed that treatment with adjunctive IN esketamine led to lower relapse rates with no considerable long-term side effects.  CONCLUSION: Intranasal esketamine was demonstrated to be safe, well tolerated, and rapidly effective in individuals with treatment resistant depression, suicidal ideation, and suicidal behavior.<p /> <p>Language: en</p>
LA  - en
SN  - 1474-0338
UR  - http://dx.doi.org/10.1080/14740338.2022.2058488
ID  - ref1
ER  -